In a significant development in the multidistrict litigation concerning Bard’s PowerPort device, a federal jury in the U.S. District Court for the District of Arizona awarded $40 million in damages last Friday. This verdict marks the conclusion of the second bellwether trial in ongoing legal proceedings that have raised concerns about alleged defects in the medical device. The PowerPort, which is designed for long-term delivery of medications and fluids, has been accused of causing serious injuries due to its purported design flaws.
The plaintiff’s case centered around claims that Bard failed to adequately warn users about risks associated with the device, which allegedly led to harm when it functioned improperly. This verdict follows the first bellwether trial where the jury similarly sided with plaintiffs, though the compensation awarded varied. Such decisions are watched closely as they often set a precedent for resolutions in other pending cases within the multidistrict litigation framework.
Becton, Dickinson and Company, which acquired Bard in 2017, has been actively addressing the legal challenges surrounding the PowerPort. The company maintains that the device is safe when used as intended and is exploring options for appeal. The outcomes of these trials could significantly influence the company’s litigation strategy and its financial liabilities moving forward.
As these proceedings continue, the broader medical community, along with manufacturers, are paying keen attention to developments. The case underscores the ongoing debate on the balance between medical innovation and patient safety. More details on the verdict can be found in an article from Law.com.